Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0032285 (pneumonia)
 54,520 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A new cephalosporin antibiotic, cefmenoxime (CMX) was administered to 22 patients aged 5 days to 8 years, and who had moderate or severe pediatric infections, to examine its clinical effect. The infections were 3 of acute bronchitis, 2 cases of asthmatic bronchitis, 6 of acute pneumonia, 1 of Mycoplasma pneumonia, 2 of sepsis (1 accompanied with pneumonia), 3 of vacterial meningitis, 2 of urinary tract infection, 1 of acute appendicitis, 1 of aseptic meningitis and 1 of fever of undetermined origin. The drug was administered by one shot intravenous injection 4 times daily at the dose of 40 approximately 200 mg/kg/day. The drug was administered for 3 approximately 15 days, the total dosage administered being 0.7 approximately 43.5 g. Clinically, excellent, good and fair response was obtained in 2, 11 and 4 cases, respectively, the drug being effective in all cases excluding the 5 cases in which judgement was unknown. The 6 strains of bacteria isolated from the lesion as the assumed causative bacteria (1 strain of S. pneumoniae, 2 of H. influenzae, 2 of E. coli, 1 of K. pneumoniae) were all eradicated after drug administration. No notable side effects were produced.
 ...
PMID:[Clinical studies on cefmenoxime in pediatric field]. 630 93

Ten swine from each of five herds believed to be affected with mycoplasmal pneumonia of swine and ten swine from each of five herds believed to be mycoplasmal pneumonia-free were selected for postmortem study. Lungs from the 100 swine were examined; grossly and microscopically for lesions typical of mycoplasmal pneumonia of swine and culturally and by an indirect immunofluorescent procedure for the presence of Mycoplasma hyopneumoniae. Nineteen of the lungs had both gross and microscopic lesions typical of mycoplasmal pneumonia of swine and 13 (68%) of these were infected, i.e. were culturally and/or indirect immunofluorescent positive. Absence of gross lesions did not prove freedom from mycoplasmal pneumonia, 14 of 73 (19%) grossly normal lungs were found to be infected with M. hyopneumoniae. Comparison of the indirect immunofluorescent and cultural examination, as methods of diagnosing mycoplasma pneumonia, revealed that neither procedure alone was reliable in the case of negative results. Ten lungs were indirect immunofluorescent negative and culturally positive and seven were culturally negative and indirect immunofluorescent positive (11 lungs were positive by both procedures). It was concluded that a definitive diagnosis of mycoplasmal pneumonia of swine requires that M. hyopneumoniae be visualized in indirect immunofluorescent stained lung sections or that it be recovered culturally.
 ...
PMID:Evaluation of criteria for the postmortem diagnosis of mycoplasmal pneumonia of swine. 643 67

Mycoplasma pneumoniae is one of the most common causes of community-acquired pneumonia. Infection is usually self-limited, but fulminant pneumonia and extrapulmonary complications can supervene. Usually, unilateral confluent, patchy, or nodular infiltrates of the lower lobe are seen on roentgenograms. Diagnosis is achieved by isolation of the organism or by serologic methods. Treatment with either erythromycin or tetracycline is effective, although organisms can be recovered during therapy. In the three cases of mycoplasmal pneumonia reported here, infection was resistant to initial therapy but patients recovered when appropriate antimicrobial therapy was instituted.
 ...
PMID:Mycoplasmal pneumonia. Three severe cases of a common infection. 649 82

Protective activity of Mycoplasma hyopneumoniae vaccines prepared from whole cells or crude extracts was evaluated in an experimentally induced mycoplasmal pneumonia swine model. Swine were obtained at 7 to 10 weeks of age from a surgically derived herd free of porcine mycoplasmas. Vaccines prepared from whole cells, freeze-thaw-saline solution extract, supernate of culture, or saline wash of cells were treated with 0.15% formalin, incorporated with Freund incomplete adjuvant, and administered IM in 2 doses. Twenty-five to 42 days after the 1st dose of vaccine was given, pigs were challenge exposed intratracheally with supernate of lung homogenate containing only M hyopneumoniae. Necropsies were done 27 to 38 days after challenge exposure. For evaluation of protective efficacy of vaccines, determination of proportion of lung with gross lesions gave better results than histologic, fluorescent antibody or mycoplasmal isolation procedures. Whole cell vaccine containing 10(9) color-changing units of M hyopneumoniae, an amount attainable in log-phase cultures, protected swine against development of pneumonia. Whole cells, supernate of culture, and saline wash of cells induced comparable protection. Protective activity of whole cell vaccine resisted heating at 80 C. Extracts prepared according to a freeze-thaw procedure were variable in protective activity and, in some instances, enhanced lesion development.
 ...
PMID:Characteristics of protective activity of Mycoplasma hyopneumoniae vaccine. 649 88

Serum concentrations of IgM and IgG antibodies in patients with Mycoplasma pneumoniae pneumonia were determined by means of the enzyme-linked immunosorbent assay. Analysis of serum specimens by treatment with protein A followed by fractionation on sucrose density gradient revealed for the first time the presence of rheumatoid factor in M. pneumoniae pneumonia with a remarkably high frequency. Development and persistence of the rheumatoid factor during the clinical course of this disease were also examined.
 ...
PMID:Immunologic responses in patients with Mycoplasma pneumoniae infections. 660 Aug 97

Mycoplasma pneumoniae pneumonia is usually a benign illness, and respiratory complications and extrapulmonary manifestations occur rarely. In this series, patients admitted to a referral hospital with this disorder had unusual symptoms, signs and findings on chest roentgenograms and laboratory studies. Pneumonia was often severe and extrapulmonary manifestations were frequent, resulting in prolonged hospital stays and illnesses. Although this extreme end of the spectrum of disease caused by M pneumoniae is not representative of this type of pneumonia as seen in outpatients, it is important to realize that patients admitted to hospital with severe, complicated pneumonia frequently have unusual manifestations of a common disease.
 ...
PMID:Mycoplasma pneumoniae pneumonia. Experience at a referral center. 674 Nov 20

Seven patients with Mycoplasma pneumoniae pneumonia presented with moderate to dense consolidation in one (in five patients) or more lobes. The diagnosis was suspected in five patients after failure to respond to 1 to 6 (average 2.6) antibiotics administered for 2 to 12 (average 7) days, and in one patient upon the development of hemolytic anemia. Clues to the diagnosis of nonbacterial pneumonia included a nonrespiratory viral-like prodromal period (in five), a nonproductive cough (in five), lack of rigors (in seven), recent "pneumonia" in family members (in ;three), normal total leukocyte and neutrophil counts (in six) and the absence of bacterial pathogens in smears and cultures of sputum (in all seven). The diagnosis of M. pneumoniae infection was supported by the presence of cold agglutinins (in a titre of 1.64 or greater) in ;the serum of five or six patients and was confirmed by diagnostic levels or increases in the titre of M. pneumoniae complement fixing antibodies. Awareness of the fact that M. pneumoniae can present as lobar consolidation and close attention to the clinical and laboratory data can usually suggest a nonbacterial cause and thus prevent delay in appropriate antibiotic treatment.
 ...
PMID:Lobar pneumonia caused by Mycoplasma pneumoniae. 678 24

Mycoplasma pneumoniae accounts for up to 35% of all pneumonias at times when influenza epidemics are not prevalent. Therefore, considerable efforts have been directed towards the developmemt of a vaccine against mycoplasmal respiratory tract disease. The protective efficacy of inactivated M. pneumoniae vaccine, prepared so far, did not exceed 67%. This incomplete protective effect may have been due to insufficient immunogenicity and/or to failure of vaccines administered by the parenteral route to stimulate local immune mechanisms on the mucosal surfaces of the respiratory tract. Intranasal inoculation of attenuated strains, either of high passage level on artificial medium or temperature-sensitive mutants, were therefore tested as vaccine candidates for M. pneumoniae disease, but the attenuation for man, achieved so far, was not sufficient. Therefore, the successful development of polysaccharide vaccines for pneumococcal and meningococcal diseases stimulated a study on similar approaches for the development of the prophylaxis for mycoplasma pneumonia. The immunogenicity and the protective efficacy of M. pneumoniae polysaccharides and glycolipids were investigated in hamsters. Staphylococcal radioimmunoassay antibodies could be detected in the sera of the animals after intramuscular injection of M. pneumoniae polysaccharides. A significant reduction in the lung lesion score and in the number of viable organisms in the lung was observed in animals immunized with polysaccharides by the intramuscular or intranasal route, 10 d after challenge with virulent organisms. A protective effect was not seen in animals previously immunized with reaggregates of M. pneumoniae glycolipids and membrane protein of Acholeplasma laidlawii, although serum antibodies could be detected prior to challenge. The results encourage the continuation of experiments on polysaccharides as vaccines against mycoplasmal pneumonia.
 ...
PMID:Protective efficacy of Mycoplasma pneumoniae polysaccharides. 679 38

Clinical trials of 9,3"-diacetylmidecamycin (MOM), a new macrolide antibiotic were carried out on 46 pediatric patients of 1 month to 11 years old with infections (acute pharyngitis 12, acute tonsillitis 1, acute bronchitis 14, asthmatic bronchitis 10, acute pneumonia 1, primary atypical pneumonia 2, Mycoplasma pneumonia 4 and pertussis 2). As a rule, MOM was given orally at a daily dose of 20 approximately 40 mg/kg divided into 3 times. The clinical results were excellent in 5 patients, good in 21, fair in 7 and poor in 13 and the efficacy rate was 56.5%. Side effects were observed in 4 patients (diarrhea, exanthema, urticaria and eosinophilia, 1 patient respectively). MOM is easy to take and a useful antibiotic for treating patients with bacterial infections, in particular, respiratory tract infection caused by Mycoplasma pneumoniae.
 ...
PMID:[Clinical studies of 9,3"-diacetylmidecamycin in pediatric field (author's transl)]. 697 41

9, 3"-Diacetylmidecamycin (MOM), a new macrolide antibiotic, was administered to 28 patients: 6 with pharyngitis caused by Group A beta-Streptococcus, 2 with lacunar tonsillitis, 8 with upper respiratory tract infection, 6 with acute bronchitis, 3 with Mycoplasma pneumonia, 1 with primary atypical pneumonia, 1 with pneumonia caused by H. influenzae and 1 with whooping cough. MOM in the form of fine granules was administered at a daily dose of about 20-30 mg/kg divided into 3 doses. Isolated group A beta-Streptococcus strains were eradicated in only 1 out of 6 strain S. One strain of H. influenzae was eradicated. The clinical results could be obtained with 21 cases and the response was excellent in 1 case, good in 7, fair in 3 and poor in 10. Although diarrhea was found in 3 cases during the administration of MOM, it was not clear whether these phenomena were caused by MOM, because of the prevalence of diarrhea among the children treated by us at that time.
 ...
PMID:[Clinical results of 9, 3"-diacetylmidecamycin dry syrup in the pediatric field (author's transl)]. 698 Feb 94


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>